Search

Displaying results 1121 - 1130 of 7554 in total
  1. Drug

    Oxogluric acid

    go.drugbank.com/drugs/DB08845
    InvestigationalNutraceutical

    Oxogluric acid is sold as a dietary supplement to athletes to improve their performance by helping to remove excess ammonia, but it is not officially approved for this indication and only experimental … Oxogluric acid (α-Ketoglutarate) is not approved for any indication in the world but is an investigational drug in the United States.

  2. Drug

    Glycyrrhizic acid

    go.drugbank.com/drugs/DB13751
    ApprovedInvestigational

    [F80] It was approved by Health Canada to be used in over-the-counter products but all the products are currently on the status canceled post marketed.[L1113] … [A33062] From January 2014, glycyrrhizic acid as part of the licorice extract was approved by the FDA as an existing food sweetener.

  3. Drug

    Defactinib

    go.drugbank.com/drugs/DB12282
    ApprovedInvestigational

    [L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian … important for the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, and its upregulation is a key resistance mechanism to

    Mixtures: Avmapki Fakzynja Co-packSynonyms: N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide
  4. Drug

    Pexidartinib

    go.drugbank.com/drugs/DB12978
    ApprovedInvestigational

    Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor … [L7895] Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors.

  5. Drug

    Promazine

    go.drugbank.com/drugs/DB00420
    ApprovedVet approvedWithdrawn

    A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. … It is currently not approved for use in the United States.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: N,N-dimethyl-3-(10H-phenothiazin-10-yl)-propan-1-amine, N-(3-Dimethylaminopropyl)phenothiazine
  6. Drug

    Esmolol

    go.drugbank.com/drugs/DB00187
    ApprovedInvestigationalWithdrawn

    It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions. … It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses.

  7. Drug

    Icosapent

    go.drugbank.com/drugs/DB00159
    ApprovedInvestigationalNutraceutical

    Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovas...

    Mixtures: UltimateCare ONE NFCategories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Non COX-2 selective NSAIDS
  8. Drug

    Benzthiazide

    go.drugbank.com/drugs/DB00562
    Approved

    Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. … Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.

  9. Drug

    Finafloxacin

    go.drugbank.com/drugs/DB09047
    ApprovedWithdrawn

    Finafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014. … Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.

  10. Drug

    Quizartinib

    go.drugbank.com/drugs/DB12874
    ApprovedInvestigational

    [A260641] Quizartinib was approved by the FDA in July 2023 and developed under the brand name VANFLYTA by Daiichi Sankyo. … cytarabine consolidation, followed by a maintenance monotherapy resulted in a 22% reduction in the risk of death.

    Synonyms: N-(5-(1,1-Dimethylethyl)isoxazol-3-yl)-N'-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1-b)benzothiazol-2-yl)phenyl)urea